Back to Screener

Healthcare

Nurix Therapeutics, Inc.(NRIX)

Live Price

Offline

$22.74

+17.82% today

1Y Change

+66.09%

Window

Jun 25, 2025 โ†’ Jun 24, 2026

Market Cap
$1.46B
Revenue Growth
+54.0%
EPS Growth
-5.9%
Dividend Yield
0.0%

Coverage: 251 bars ยท Jun 25, 2025 โ†’ Jun 24, 2026

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

Nurix Therapeutics, Inc. (NRIX) is a Healthcare stock with a market cap of $1.46B and listed on NASDAQ. The stock last traded around $22.74 and up 66.1% across the available one-year price window (Jun 25, 2025 โ†’ Jun 24, 2026). Baseline metrics include revenue growth of +54.0%, EPS growth of -5.9%, a dividend yield of 0.0%. What stands out right now is revenue +54.0%, EPS -5.9%, free cash flow -44.9% with operating margin -439.3% and ROIC -57.6%. Valuation already assumes a fairly strong business story at price/sales 20.3. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines NRIX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.

Benchmark Edge

NRIX vs SPY, QQQ, and Sector ETFs

Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.

Shared 1Y chart + MAX history table

NRIX

โ€”

Normalized return

SPY

--

S&P 500

Excess Return

--

Relative to SPY

NRIX Max Drawdown

-37.48%

Trailing 1Y

SPY Max Drawdown

โ€”

Trailing 1Y

Benchmark comparison is loading or unavailable right now.

Calendar-Year Returns

Uses the longest available daily history for NRIX and SPY.

Calendar-year return history is still loading or unavailable.

Unable to load analyst forecasts.

Timed out loading forecasts for NRIX

Next Step

Put consensus data in context

Forecasts are most valuable when they sit beside comparisons, earnings setup, and the rest of the business story.